Why healthcare leaders should pay attention to the lymphatic system | Viewpoint

For decades, the lymphatic system has been one of medicine’s most overlooked frontiers.

Despite its essential role in immune function, fluid balance, and overall health, the lymphatic system has received only a fraction of the attention devoted to other major body systems. The consequences are significant. Millions of Americans live with chronic lymphatic diseases. Many face delayed diagnoses, limited treatment options, and difficulty accessing specialized care. That reality may finally be changing.

This year, after years of focused advocacy, the federal government’s Advanced Research Projects Agency for Health (ARPA-H) committed nearly $300 million to research teams at leading medical institutions across the United States to fast-track the development of new diagnostics, imaging technologies, medical devices, and treatments for lymphatic diseases. This is the largest coordinated investment ever made in this field.

The work already underway illustrates the scale of what is possible. At Stanford University, researchers are developing a tiny implant paired with a therapeutic drug designed to help patients regrow damaged lymphatic vessels and restore normal drainage. At Columbia University, scientists are using advanced genomic tools to improve the diagnosis and classification of pediatric lymphatic anomalies to help children receive faster, more precise care. Researchers at Rice University are developing next-generation imaging technologies that could allow clinicians to identify and monitor lymphatic diseases with far greater accuracy.

These projects are part of a broader effort to move lymphatic medicine from a field defined by delayed diagnosis and limited treatment options to one led by precision diagnostics and earlier intervention.

For healthcare leaders, however, the significance of this investment extends beyond the science itself. The real question is not whether breakthrough technologies will emerge. It is whether our healthcare system will be prepared to translate those breakthroughs into meaningful improvements in patient care.

Consider lymphedema, a chronic disease caused by damage or dysfunction of the lymphatic system that leads to significant and debilitating swelling. More than 10 million Americans are affected, including approximately one in five breast cancer survivors. Yet many patients spend years seeking answers, encounter clinicians with limited training in lymphatic disorders, or struggle to find specialized treatment programs. Research has shown the average American medical school graduate receives less than 30 minutes of dedicated education on the lymphatic system over four years of training.

Even the most promising new diagnostic tool or therapy will have limited impact if healthcare systems are not prepared to identify appropriate patients, integrate new technologies into clinical workflows, educate providers, and ensure access to specialized care.

Healthcare systems should begin evaluating their readiness for what comes next. Do providers have sufficient awareness of lymphatic diseases and emerging treatment approaches? Are referral pathways in place to connect patients with specialists? Do multidisciplinary teams exist to support patients whose conditions often intersect with oncology, vascular medicine, rehabilitation, surgery, and primary care? These questions matter because the impact of this research will likely extend far beyond a single disease category.

Researchers increasingly recognize that the lymphatic system plays a critical role throughout the body. New discoveries could influence how clinicians understand cancer progression, neurodegenerative diseases such as Alzheimer’s, chronic inflammation, immune dysfunction, and a range of other conditions that drive significant healthcare utilization and costs.

In other words, this is not simply a rare or niche area of medicine. It is a foundational area of human biology whose influence may reach across multiple specialties and care settings.

As someone who has spent years working alongside patients, researchers, clinicians, and advocates in the lymphatic community, I believe the ARPA-H investment represents a historic milestone. But its ultimate success will not be measured solely by the technologies developed in research laboratories. It will be measured by whether patients receive earlier diagnoses, better treatments, improved quality of life, and greater access to expert care.

That outcome will depend not only on scientists and innovators, but also on healthcare leaders willing to build the clinical pathways, provider education, and patient-centered infrastructure needed to turn discovery into impact.

The research is underway. Now the healthcare system must be ready to meet the moment.

William Repicci is president and CEO of the nonprofit Lymphatic Education and Research Network (LE&RN).